PMID- 37261001
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240320
IS  - 2048-8505 (Print)
IS  - 2048-8513 (Electronic)
IS  - 2048-8505 (Linking)
VI  - 16
IP  - 6
DP  - 2023 Jun
TI  - Challenges of defining renal response in ANCA-associated vasculitis: call to 
      action?
PG  - 965-975
LID - 10.1093/ckj/sfad009 [doi]
AB  - Avoiding end-stage kidney disease in patients with anti-neutrophil cytoplasmic 
      antibody-associated vasculitis (AAV) has a high therapeutic priority. Although 
      renal response is a crucial measure to capture clinically relevant changes, 
      clinal trials have used various definitions and no well-studied key surrogate 
      markers to predict renal outcome in AAV exist. Differences in clinical features 
      and histopathologic and therapeutic approaches will influence the course of 
      kidney function. Its assessment through traditional surrogates (i.e. serum 
      creatinine, glomerular filtration rate, proteinuria, hematuria and disease 
      activity scores) has limitations. Refinement of these markers and the 
      incorporation of novel approaches such as the assessment of histopathological 
      changes using cutting-edge molecular and machine learning mechanisms or new 
      biomarkers could significantly improve prognostication. The timing is favourable 
      since large datasets of trials conducted in AAV are available and provide a 
      valuable resource to establish renal surrogate markers and, likely, aim to 
      investigate optimized and tailored treatment approaches according to a renal 
      response score. In this review we discuss important points missed in the 
      assessment of kidney function in patients with AAV and point towards the 
      importance of defining renal response and clinically important short- and 
      long-term predictors of renal outcome.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
FAU - Odler, Balazs
AU  - Odler B
AD  - Division of Nephrology, Department of Internal Medicine, Medical University of 
      Graz, Graz, Austria.
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Bruchfeld, Annette
AU  - Bruchfeld A
AUID- ORCID: 0000-0002-9752-9941
AD  - Department of Clinical Science, Intervention and Technology, Division of Renal 
      Medicine Karolinska Institutet, Stockholm, Sweden.
AD  - Department of Health, Medicine and Caring Sciences, Linkopings Universitet, 
      Linkoping, Sweden.
FAU - Scott, Jennifer
AU  - Scott J
AD  - Trinity Health Kidney Center, Trinity Translational Medicine Institute, Trinity 
      College Dublin, Dublin, Ireland.
FAU - Geetha, Duvuru
AU  - Geetha D
AD  - Division of Nephrology, Department of Medicine, School of Medicine, Johns Hopkins 
      University, Baltimore, MD, USA.
FAU - Little, Mark A
AU  - Little MA
AUID- ORCID: 0000-0001-6003-397X
AD  - Trinity Health Kidney Center, Trinity Translational Medicine Institute, Trinity 
      College Dublin, Dublin, Ireland.
FAU - Jayne, David R W
AU  - Jayne DRW
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
FAU - Kronbichler, Andreas
AU  - Kronbichler A
AD  - Department of Medicine, University of Cambridge, Cambridge, UK.
LA  - eng
GR  - J 4664/FWF_/Austrian Science Fund FWF/Austria
PT  - Journal Article
PT  - Review
DEP - 20230111
PL  - England
TA  - Clin Kidney J
JT  - Clinical kidney journal
JID - 101579321
PMC - PMC10229283
OTO - NOTNLM
OT  - ANCA vasculitis
OT  - ESKD
OT  - kidney function
OT  - outcome
OT  - renal response
COIS- B.O. has received speaker fees and travel support from Otsuka. A.B. is member of 
      the CKJ editorial board and has received consulting and speaker fees from 
      AstraZeneca, Bayer, ChemoCentryx, Fresenius, Merck/MSD and Vifor. D.G. has 
      received consulting fees from ChemoCentryx, GlaxoSmithKline and Aurinia. D.J. has 
      received consultancy or lecture fees from Amgen, AstraZeneca, Bristol-Myers 
      Squibb, ChemoCentryx, CSL Vifor, Novartis, Otsuka, Roche and Takeda. A.K. is 
      member of the CKJ editorial board and has received consulting fees from Vifor 
      Pharma, Otsuka, Delta 4, UriSalt and Catalyst Biosciences. The other authors 
      declared no conflicts of interest related to this work.
EDAT- 2023/06/01 13:09
MHDA- 2023/06/01 13:10
PMCR- 2023/01/11
CRDT- 2023/06/01 10:34
PHST- 2022/09/16 00:00 [received]
PHST- 2023/06/01 13:10 [medline]
PHST- 2023/06/01 13:09 [pubmed]
PHST- 2023/06/01 10:34 [entrez]
PHST- 2023/01/11 00:00 [pmc-release]
AID - sfad009 [pii]
AID - 10.1093/ckj/sfad009 [doi]
PST - epublish
SO  - Clin Kidney J. 2023 Jan 11;16(6):965-975. doi: 10.1093/ckj/sfad009. eCollection 
      2023 Jun.